review focu turn busi
fundament pt sector multipl
gilead report sales/earn provid investor updat
quarter line consensu estim miss opco
expect see top line bottom line due one-off
hiv/hcv franchis compani still manag opex smartli continu
trend maintain adjust oper margin new manag cfo/
slot expect updat commerci execut pipelin
hiv continu strong hcv stabil yescarta still surpris quarterli
variat filgotinib file timelin us/ex-u file firm
adjust number go forward trim pt due
sector multipl compress stay bullish
sale affect time hiv/hcv reimburs
clawback led declin adjust
number reflect one-off still expect grow upgrad
thesi earli howev anoth hcv sale step-down potenti
soften biktarvi yescarta sale growth might give investor paus
point hiv yescarta hcv franchis better expect
given recent approv descovi prep final
rule reimburs car-t therapi biktarvi approv
china recent note week believ hiv
yescarta sale growth might paus hcv still wild card
filgotinib file eu japan us nda
file cautiou assum class label filgotinib infect
thrombosi etc believ two-dos regimen strong risk/benefit
profil could make filgotinib best-in-class recent kol call us
given us addit confid thesi
note call got mani fundament question variou
aspect busi continu focu peer-group better margin
post-cfo transit science-driven bd etc vs previou hyper-focu hcv
and/or yescarta check indic clinic trial car-t therapi
potenti impact yescarta sale merit
under-perform biotech sector slightli vs nbi index ytd
howev continu like name sinc busi fundament
improv protect drug class hiv keep govern scrutini
competit intens bay dividend yield expect grow
annual manag focus broadening/deepen pipelin
year price histori
gilead develop commerci
innov medicin area unmet
treatment hiv/aid liver diseas
cancer inflamm
analyst certif import disclosur see disclosur
hcv sale declin slowli stabil
hiv busi launch taf-bas regimen bic/f/taf
make hiv solid growth busi
yescarta axi-cel launch across us eu meet
expect sale
cardiovascular/oth busi sale reduc
due gener competit
non-gaap oper margin declin
rebound
believ addit savvi industri
veteran daniel day ceo announc year-
on-year sale growth import mid/late-stag clinic
readout bud franchis inflamm filgotinib
nash nash combin trial could start re-rat biotech
bellweth name among cheapest large-cap
submit nda filgotinib ra data atla
phase studi phase studi data segatolimod hbv
submit descovi prep
complet list catalyst exhibit
hcv sale trough next two four quarter stable/up
patient diagnos treat
hiv busi outperform expect
yescarta us/eu launch beat reduc expect provid
abl start grow margin onward
hcv busi continu declin precipit rate near
hiv busi growth minim best next two five year
yescarta us/eu launch underperform reduc expect due
car-t side-effect manufactur reimburs concern
nash franchis gain traction clinic data
mediocr best
pt employ composit valuat methodolog biotechnolog compani util forward price-to-earnings
multipl npv adjust non-gaap estim earn sinc biotechnolog sector high-growth/high-expect
rank target compani base qualiti sale and/or earn growth versu peer group
peer index nbi index expect earn growth next three five year expect
appli lower termin multipl adj ep lower sales/earn growth trajectori vs peer
group appli discount rate gild valuat peer group averag
risk thesi includ follow
continu see sale declin margin deterior
mid/late-stag pipelin project inflamm filgotinib nash selonsertib combin trial nash unsuccess
new ceo oday abl execut acquisition/licens strategi help fundament strengthen faster expect
million except per opcovariancenet product royalti contract total good research sell gener non-gaap oper non-gaap oper non-gaap incom expens interest non-gaap incom incom incom tax non-gaap net net loss attribut non control net incom attribut dilut dilut share inc
revenu hcv hiv total selonsirtib- total total product outperform
exhibit reiter commit sharehold return
 vosevi- hcv vemlidy- biktarvy- hiv total yescarta- selonsirtib- filgotinib- total total product inc
statement million except per product royalti contract total good research sell gener non-gaap oper non-gaap oper non-gaap incom expens interest non-gaap incom incom incom tax non-gaap net net loss attribut non control net incom attribut dilut dilut share adjust comp gross oper incom tax outperform
npv cagrcommentstot revenu ebitda net incom decreas y/i tax rate us adj ep compound-annual-growth-rate group index nbi indexp group adj ep compound-annual-growth-rate expect nbi index ep ltgpeer group termin price-to-earnings multipl multipl large-cap peer group opco estimatesgild us termin price-to-earnings multipl peer group sale ep flat slightli valu us wacc peer group averag per bloomberggild us discount rate adj ep price-to-earnings valuat inc
capsid phase studi highli treatment experienc patient phase studi treatment-nav phase studyhematology/oncologyyescarta axicabtagen registr studi indol nhl phase combin studi atezolizumab data phase combin studi agonist enrol phase studi line high risk dlbcl analysi studi cohort evalu earli steroid intervent phase phase studi cll registr phase studi mcl enrol phase studi mage solid clinic studi allogen totherremdesivir enrol phase studi ebola survivorsnash pbc psc updat phase studi diabet kidney fxr enrol phase studi phase studycombin data atla phase studi selonsertib and/or and/or patient advanc fibrosi due data phase poc studi firsocostat cilofexor select phase studi nda us phase studi ankylos enrol divers phase studi crohn phase studi cutan lupu phase studi sjogren syndrom data examin disclosur futur medic phase studi data phase studi ipf patient phase studi osteoarthr outperform
